Patents by Inventor Debashis MANDAL
Debashis MANDAL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11931343Abstract: Compounds, such as compounds having Formula (I): wherein each variable is as described herein, that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.Type: GrantFiled: August 26, 2019Date of Patent: March 19, 2024Assignee: Arcus Biosciences, Inc.Inventors: Joel Beatty, Laurent Pierre Paul Debien, Samuel Lawrie Drew, Jeremy Fournier, Rebecca Louise Grange, Steven Donald Jacob, Jenna Leigh Jeffrey, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Debashis Mandal, Jay Patrick Powers, Anh Thu Tran, Rhiannon Thomas-Tran, Xuelei Yan
-
Patent number: 11787762Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.Type: GrantFiled: June 8, 2022Date of Patent: October 17, 2023Assignee: ARCUS BIOSCIENCES, INC.Inventors: Joel Worley Beatty, Samuel Lawrie Drew, Matthew Epplin, Jeremy Thomas Andre Fournier, Balint Gal, Tezcan Guney, Karl T. Haelsig, Clayton Hardman, Steven Donald Jacob, Jenna Leigh Jeffrey, Jaroslaw Kalisiak, Kenneth Victor Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Artur Karenovich Mailyan, Debashis Mandal, Guillaume Mata, Hyunyoung Moon, Jay Patrick Powers, Brandon Reid Rosen, Yongli Su, Anh Thu Tran, Zhang Wang, Xuelei Yan, Kai Yu
-
Publication number: 20230024438Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.Type: ApplicationFiled: December 3, 2020Publication date: January 26, 2023Inventors: Joel Worley BEATTY, Samuel Lawrie DREW, Jeremy Thomas Andre FOURNIER, Tezcan GUNEY, Steven Donald JACOB, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Debashis MANDAL, Guillaume MATA, Jay Patrick POWERS, Brandon Reid ROSEN, Yongli SU, Anh Thu TRAN, Xuelei YAN
-
Publication number: 20230021476Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.Type: ApplicationFiled: June 8, 2022Publication date: January 26, 2023Inventors: Joel Worley BEATTY, Samuel Lawrie DREW, Matthew EPPLIN, Jeremy Thomas Andre FOURNIER, Balint GAL, Tezcan GUNEY, Karl T. HAELSIG, Clayton HARDMAN, Steven Donald JACOB, Jenna Leigh JEFFREY, Jaroslaw KALISIAK, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Artur Karenovich MAILYAN, Debashis MANDAL, Guillaume MATA, Hyunyoung MOON, Jay Patrick POWERS, Brandon Reid ROSEN, Yongli SU, Anh Thu TRAN, Zhang WANG, Xuelei YAN, Kai YU
-
Patent number: 11407712Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.Type: GrantFiled: March 18, 2021Date of Patent: August 9, 2022Assignee: ARCUS BIOSCIENCES, INC.Inventors: Joel Worley Beatty, Samuel Lawrie Drew, Matthew Epplin, Jeremy Thomas Andre Fournier, Balint Gal, Tezcan Guney, Karl T. Haelsig, Clayton Hardman, Steven Donald Jacob, Jenna Leigh Jeffrey, Jaroslaw Kalisiak, Kenneth Victor Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Artur Karenovich Mailyan, Debashis Mandal, Guillaume Mata, Hyunyoung Moon, Jay Patrick Powers, Brandon Reid Rosen, Yongli Su, Anh Thu Tran, Zhang Wang, Xuelei Yan, Kai Yu
-
Publication number: 20220144808Abstract: Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.Type: ApplicationFiled: October 22, 2021Publication date: May 12, 2022Inventors: Joel BEATTY, Laurent DEBIEN, Jenna JEFFREY, Manmohan Reddy LELETI, Debashis MANDAL, Dillon MILES, Jay POWERS, Brandon ROSEN, Ehesan SHARIF, Rhiannon THOMAS-TRAN
-
Publication number: 20220016143Abstract: Compounds that are inhibitors of at least one of ARG1 and ARG2, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by ARG1 and ARG2 are also described herein.Type: ApplicationFiled: November 15, 2019Publication date: January 20, 2022Inventors: Joel BEATTY, Eric Thomas NEWCOMB, Jay Patrick POWERS, Brandon Reid ROSEN, Yongli SU, Anh Thu TRAN, Corinne Nicole FOLEY, Rebecca Louise GRANGE, Tezcan GUNEY, Steven Donald JACOB, Jaroslaw KALISIAK, Manmohan Reddy LELETI, Erick Allen LINDSEY, Debashis MANDAL
-
Publication number: 20210346353Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.Type: ApplicationFiled: August 26, 2019Publication date: November 11, 2021Inventors: Joel BEATTY, Laurent Pierre Paul DEBIEN, Samuel Lawrie DREW, Jeremy FOURNIER, Rebecca Louise GRANGE, Steven Donald JACOB, Jenna Leigh JEFFREY, Kenneth V. LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Debashis MANDAL, Jay Patrick POWERS, Anh Thu TRAN, Rhiannon THOMAS-TRAN, Xuelei YAN
-
Publication number: 20210317079Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.Type: ApplicationFiled: March 18, 2021Publication date: October 14, 2021Inventors: Joel Worley BEATTY, Samuel Lawrie DREW, Matthew EPPLIN, Jeremy Thomas Andre FOURNIER, Balint GAL, Tezcan GUNEY, Karl T. HAELSIG, Clayton HARDMAN, Steven Donald JACOB, Jenna Leigh JEFFREY, Jaroslaw KALISIAK, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Artur Karenovich MAILYAN, Debashis MANDAL, Guillaume MATA, Hyunyoung MOON, Jay Patrick POWERS, Brandon Reid ROSEN, Yongli SU, Anh Thu TRAN, Zhang WANG, Xuelei YAN, Kai YU
-
Patent number: 11072597Abstract: Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.Type: GrantFiled: July 2, 2019Date of Patent: July 27, 2021Inventors: Joel Beatty, Laurent Debien, Jenna Jeffrey, Manmohan Reddy Leleti, Debashis Mandal, Dillon Miles, Jay Powers, Brandon Rosen, Ehesan Sharif, Rhiannon Thomas-Tran
-
Patent number: 11046628Abstract: The present invention refers to a process for transition-metal-assisted 18F-deoxyfluorination of phenols. The transformation benefits from readily available phenols as starting materials, tolerance of moisture and ambient atmosphere, large substrate scope, and translatability to generate doses appropriate for positron emission tomography (PET) imaging.Type: GrantFiled: July 10, 2018Date of Patent: June 29, 2021Assignee: STUDIENGESELLSCHAFT KOHLE MBHInventors: Tobias Ritter, Constanze Neumann, Mohammad Hassan Beyzavi, Martin Georg Strebl-Bantillo, Debashis Mandal
-
Publication number: 20210161898Abstract: Compound that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.Type: ApplicationFiled: July 26, 2019Publication date: June 3, 2021Inventors: Manmohan Reddy LELETI, Debashis MANDAL, Dillon Harding MILES, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF
-
Publication number: 20210101880Abstract: Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.Type: ApplicationFiled: July 2, 2019Publication date: April 8, 2021Inventors: Joel BEATTY, Laurent DEBIEN, Jenna JEFFREY, Manmohan Reddy LELETI, Debashis MANDAL, Dillon MILES, Jay POWERS, Brandon ROSEN, Ehesan SHARIF, Rhiannon THOMAS-TRAN
-
Patent number: 10889590Abstract: In one aspect, the present disclosure provides new analogs of uncialamycin. The present disclosure also provides novel synthetic pathways to obtaining uncialamycin and analogs thereof. Additionally, the present disclosure also describes methods of use of uncialamycin and analogs thereof. In another aspect, the present disclosure provides antibody-drug conjugates which may be used to treat cancer or another disease or disorder.Type: GrantFiled: March 18, 2019Date of Patent: January 12, 2021Assignees: William Marsh Rice University, The Scripps Research Institute, Bristol-Myers Squibb CompanyInventors: Kyriacos C. Nicolaou, Min Lu, Debashis Mandal, Sanjeev Gangwar, Naidu S. Chowdari, Yam B. Poudel
-
Publication number: 20200369583Abstract: The present invention refers to a process for transition-metal-assisted 18F-deoxyfluorination of phenols. The transformation benefits from readily available phenols as starting materials, tolerance of moisture and ambient atmosphere, large substrate scope, and translatability to generate doses appropriate for positron emission tomography (PET) imaging.Type: ApplicationFiled: July 10, 2018Publication date: November 26, 2020Applicants: STUDIENGESELLSCHAFT KOHLE MBH, PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Tobias RITTER, Constanze NEUMANN, Mohammad Hassan BEYZAVI, Martin Georg STREBL-BANTILLO, Debashis MANDAL
-
Patent number: 10808007Abstract: In one aspect, the present disclosure provides tubulysin analogs of the formula (I) wherein R1, R2, R3, R4, X1, X2, X3, and A1 are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein.Type: GrantFiled: February 25, 2016Date of Patent: October 20, 2020Assignee: William Marsh Rice UniversityInventors: Kyriacos C. Nicolaou, Dionisios Vourloumis, Jun Yin, Rohan Erande, Debashis Mandal, Phillipp Klahn
-
Publication number: 20190382412Abstract: In one aspect, the present disclosure provides new analogs of uncialamycin. The present disclosure also provides novel synthetic pathways to obtaining uncialamycin and analogs thereof. Additionally, the present disclosure also describes methods of use of uncialamycin and analogs thereof. In another aspect, the present disclosure provides antibody-drug conjugates which may be used to treat cancer or another disease or disorder.Type: ApplicationFiled: March 18, 2019Publication date: December 19, 2019Applicants: WILLIAM MARSH RICE UNIVERSITY, BRISTOL-MYERS SQUIBB COMPANY, THE SCRIPPS RESEARCH INSTITUTEInventors: Kyriacos C. Nicolaou, Min LU, Debashis MANDAL, Sanjeev GANGWAR, Naidu S. CHOWDARI, Yam B. POUDEL
-
Patent number: 10399962Abstract: Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.Type: GrantFiled: January 19, 2018Date of Patent: September 3, 2019Assignee: ARCUS BIOSCIENCES, INC.Inventors: Joel Beatty, Laurent Debien, Jenna Jeffrey, Manmohan Reddy Leleti, Debashis Mandal, Dillon Miles, Jay Powers, Brandon Rosen, Ehesan Sharif, Rhiannon Thomas-Tran
-
Patent number: 10233192Abstract: In one aspect, the present disclosure provides new analogs of uncialamycin. The present disclosure also provides novel synthetic pathways to obtaining uncialamycin and analogs thereof. Additionally, the present disclosure also describes methods of use of uncialamycin and analogs thereof. In another aspect, the present disclosure provides antibody-drug conjugates which may be used to treat cancer or another disease or disorder.Type: GrantFiled: August 15, 2017Date of Patent: March 19, 2019Assignees: WILLIAM MARSH RICE UNIVERSITY, THE SCRIPPS RESEARCH INSTITUTE, BRISTOL-MYERS SQUIBB COMPANYInventors: Kyriacos C. Nicolaou, Min Lu, Debashis Mandal, Sanjeev Gangwar, Naidu S. Chowdari, Yam B. Poudel
-
Publication number: 20180215730Abstract: Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.Type: ApplicationFiled: January 19, 2018Publication date: August 2, 2018Inventors: Joel BEATTY, Laurent DEBIEN, Jenna JEFFREY, Manmohan Reddy LELETI, Debashis MANDAL, Dillon MILES, Jay POWERS, Brandon ROSEN, Ehesan SHARIF, Rhiannon THOMAS-TRAN